•
Sep 30, 2022
Keros Q3 2022 Earnings Report
Reported financial results for the quarter ended September 30, 2022.
Key Takeaways
Keros Therapeutics reported a net loss of $23.5 million in the third quarter of 2022. The company's cash and cash equivalents as of September 30, 2022 was $239.4 million and expects to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.
Keros continued to build upon the positive momentum of pipeline programs in the third quarter of 2022.
Presented encouraging data from the multiple ascending dose portion of Phase 1 clinical trial of KER-012 in healthy volunteers.
Team is focused on initiating the Phase 2 clinical trial in pulmonary arterial hypertension, and expects to share the design of this trial in early 2023.
Strengthened balance sheet to extend cash runway into the first quarter of 2025.